Want to see INBX full AI Analyst Report?
INBX Stock Chart & Stats
$85.32
-$0.31(-2.00%)
At close: 4:00 PM EST
$85.32
-$0.31(-2.00%)
Day’s Range― - ―
52-Week Range$13.97 - $155.29
Previous CloseN/A
Volume23.61K
Average Volume (3M)434.66K
Market Cap
$1.39B
Enterprise Value$1.23B
Total Cash (Recent Filing)$161.66M
Total Debt (Recent Filing)$5.90M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Aug 19, 2026EPS Estimate
-2.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.39
Shares Outstanding14,671,186
10 Day Avg. Volume333,594
30 Day Avg. Volume434,660
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)153.07
Price to Sales (P/S)941.13
P/FCF Ratio-9.42
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue943.29
Enterprise Value/Gross Profit-2.65K
Enterprise Value/Ebitda-10.47
Forecast
1Y Price Target
$277.50Price Target Upside225.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-7.83
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Milestone: BLA Accepted For OzekibartFDA acceptance starts a formal review clock and signals the submission met filing standards. This materially reduces near-to-medium term regulatory uncertainty for ozekibart and creates a clear, durable pathway to first commercial product potential and partner/license negotiation leverage.
Pivotal ChonDRAgon Trial Showed Strong PFS BenefitA robust pivotal efficacy signal (52% risk reduction, doubled PFS) materially strengthens the approval case and clinical differentiation in a rare disease with no approved systemic therapy. That durable clinical validity underpins potential market exclusivity and long-term commercial value for ozekibart.
Pipeline Diversification: INBRX-106 Advancing To Phase 3A second mid/late-stage program expanding into Phase 3 diversifies the company beyond a single near-term asset. Durable portfolio breadth improves strategic optionality, lowers single-asset commercialization risk, and supports larger addressable markets if Phase 3 confirms the early efficacy signals.
Bears Say
Substantial Cash Burn And Negative Free Cash FlowPersistent negative operating and free cash flow of roughly $132M TTM creates a structural dependence on external financing to fund development and potential launch activities. This raises dilution risk, limits strategic flexibility, and may constrain investment pacing absent financing alternatives.
Minimal Revenue With Large Ongoing LossesVery low revenue against steep, recurring losses indicates no commercial scale and negative operating leverage. This sustained lack of revenue diversification undermines self-funding capacity, heightens reliance on capital markets, and makes achieving positive margins a multi-period structural challenge.
Negative Stockholders' Equity And Weakened Balance SheetNegative shareholders' equity reflects accumulated losses and reduces balance-sheet flexibility. Even with low absolute debt, negative equity elevates financing sensitivity, may complicate partner or payer negotiations, and is a durable constraint on capital structure and strategic optionality.
Inhibrx Biosciences Inc News
INBX FAQ
What was Inhibrx Biosciences, Inc.’s price range in the past 12 months?
Inhibrx Biosciences, Inc. lowest stock price was $13.97 and its highest was $155.29 in the past 12 months.
What is Inhibrx Biosciences, Inc.’s market cap?
Inhibrx Biosciences, Inc.’s market cap is $1.39B.
When is Inhibrx Biosciences, Inc.’s upcoming earnings report date?
Inhibrx Biosciences, Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 51 days.
How were Inhibrx Biosciences, Inc.’s earnings last quarter?
Inhibrx Biosciences, Inc. released its earnings results on May 14, 2026. The company reported -$2.15 earnings per share for the quarter, missing the consensus estimate of -$1.675 by -$0.475.
Is Inhibrx Biosciences, Inc. overvalued?
According to Wall Street analysts Inhibrx Biosciences, Inc.’s price is currently Undervalued.
Does Inhibrx Biosciences, Inc. pay dividends?
Inhibrx Biosciences, Inc. pays a Notavailable dividend of $0.85 which represents an annual dividend yield of N/A. See more information on Inhibrx Biosciences, Inc. dividends here
What is Inhibrx Biosciences, Inc.’s EPS estimate?
Inhibrx Biosciences, Inc.’s EPS estimate is -2.28.
How many shares outstanding does Inhibrx Biosciences, Inc. have?
Inhibrx Biosciences, Inc. has 14,671,186 shares outstanding.
What happened to Inhibrx Biosciences, Inc.’s price movement after its last earnings report?
Inhibrx Biosciences, Inc. reported an EPS of -$2.15 in its last earnings report, missing expectations of -$1.675. Following the earnings report the stock price went down -6.474%.
Which hedge fund is a major shareholder of Inhibrx Biosciences, Inc.?
Currently, no hedge funds are holding shares in INBX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inhibrx Biosciences Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$277.50 (225.25% Upside)
$277.50 (225.25% Upside)
Blogger Sentiment
Bullish
INBX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 240.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 7.3%
Last 30 Days ▲ 7.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
541.04%
12-Months-Change
Fundamentals
Return on Equity
-563.89%
Trailing 12-Months
Asset Growth
-24.18%
Trailing 12-Months
Company Description
Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.
INBX Stock 12 Month Forecast
Average Price Target
$277.50
▲(225.25% Upside)
Technical Analysis
Prothena
―
CytomX Therapeutics
―
Humacyte
―
Monte Rosa Therapeutics
―
Candel Therapeutics
―
Ownership Overview
9.66% Insiders
8.32% Mutual Funds
45.63% Other Institutional Investors
24.89% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---